DR Reddy S Laboratories Limited — Omeprazole Exporter Profile
Indian Pharmaceutical Exporter · #9 for Omeprazole · $41.1M export value · DGFT Verified
DR Reddy S Laboratories Limited is the #9 Indian exporter of Omeprazole with $41.1M in export value and 108 verified shipments. DR Reddy S Laboratories Limited holds a 0.8% market share in Omeprazole exports across 9 countries. The company exports 50 pharmaceutical products worth $310.6M across 19 therapeutic categories.
DR Reddy S Laboratories Limited — Omeprazole Export Profile: Buyers & Destinations
Where Does DR Reddy S Laboratories Limited Export Omeprazole?
| Country | Value | Shipments | Share |
|---|---|---|---|
| UNITED STATES | $8.4M | 247 | 73.3% |
| UNITED STATES OF AMERICA | $1.1M | 28 | 9.7% |
| SOUTH AFRICA | $717.1K | 15 | 6.2% |
| MEXICO | $445.5K | 10 | 3.9% |
| KAZAKHSTAN | $190.0K | 4 | 1.7% |
| BELARUS | $177.4K | 43 | 1.5% |
| NEW ZEALAND | $100.0K | 2 | 0.9% |
| KAZAKISTAN | $79.2K | 2 | 0.7% |
| LATVIA | $79.2K | 7 | 0.7% |
| LITHUANIA | $71.2K | 10 | 0.6% |
DR Reddy S Laboratories Limited exports Omeprazole to 14 countries. The largest destination is UNITED STATES accounting for 73.3% of DR Reddy S Laboratories Limited's Omeprazole shipments, followed by UNITED STATES OF AMERICA (9.7%) and SOUTH AFRICA (6.2%). These destinations reflect DR Reddy S Laboratories Limited's established distribution network and regulatory approvals in key markets.
Who Are the Top Buyers of Omeprazole from DR Reddy S Laboratories Limited?
| Buyer | Country | Value | Orders |
|---|---|---|---|
| DR REDDYS LABORATORIES INC | UNITED STATES | $3.9M | 120 |
| DR REDDY SLABORATORIES INC | UNITED STATES | $1.7M | 47 |
| NORTHSTAR DISTRIBUTION CENTER 8912 | UNITED STATES | $1.1M | 34 |
| NORTHSTAR DISTRIBUTION CENTER | UNITED STATES | $690.9K | 21 |
| DR REDDY S LABORATORIES INC | UNITED STATES | $521.3K | 15 |
| DR REDDYS LABORATORIES S A | UNITED STATES | $399.3K | 8 |
| XX REXXY SXXABOXXTORXXS XX AX | UNITED STATES OF AMERICA | $249.4K | 5 |
| PRIORITY HEALTHCARE DISTRIBUTION DB | UNITED STATES | $223.7K | 9 |
| REED LANE INC | UNITED STATES | $200.0K | 4 |
| SIEGFRIED RHEIN SADE CV | MEXICO | $200.0K | 4 |
DR Reddy S Laboratories Limited supplies Omeprazole to 59 buyers globally. The largest buyer is DR REDDYS LABORATORIES INC (UNITED STATES), followed by DR REDDY SLABORATORIES INC (UNITED STATES) and NORTHSTAR DISTRIBUTION CENTER 8912 (UNITED STATES). These buyers represent pharmaceutical distributors, hospital groups, and government procurement agencies in their respective markets.
What Is India's Total Omeprazole Export Value and How Much Does DR Reddy S Laboratories Limited Contribute?
India exported $248.0M worth of Omeprazole through 15,000 shipments from 975 suppliers to 179 countries, serving 2,858 buyers globally. DR Reddy S Laboratories Limited contributes $41.1M to this total, accounting for 0.8% of India's Omeprazole exports. DR Reddy S Laboratories Limited ships Omeprazole to 14 countries through 59 buyers.
What Is the Average Shipment Value for DR Reddy S Laboratories Limited's Omeprazole Exports?
DR Reddy S Laboratories Limited's average Omeprazole shipment value is $380.6K per consignment, based on 108 shipments totaling $41.1M. The largest destination is UNITED STATES (73.3% of DR Reddy S Laboratories Limited's Omeprazole exports).
How Does DR Reddy S Laboratories Limited Compare to Other Indian Omeprazole Exporters?
DR Reddy S Laboratories Limited ranks #9 among 975 Indian Omeprazole exporters with a 0.8% market share. The top 3 exporters are SUN PHARMACEUTICAL INDUSTRIES LIMITED ($53.6M), CIPLA LIMITED ($44.0M), DR.REDDY'S LABORATORIES LTD ($35.7M). DR Reddy S Laboratories Limited processed 108 shipments to 9 destination countries.
What Omeprazole Formulations Does DR Reddy S Laboratories Limited Export?
| Product Description / Formulation | Value | Shipments |
|---|---|---|
| OMEPRAZOLE MAGNESIUM DELAYED RELEASE | $748.6K | 15 |
| 300038464 OmeprazoleDRCapstUSP20mg1000sQ | $223.7K | 9 |
| OMEPRAZOLE DELAYED-RELEASE CAPSULES USP20MG 1000S 5897 X 1000S PACKS=5897000 NOS | $150.0K | 3 |
| OMEPRAZOLE DR CAPSULES USP 40MG 11520x100's PACK | $103.5K | 5 |
| NAPROXEN AND ESOMEPRAZOLE MG DR TABS 500/20MG 60 S 6024 X 60 S PACKS= 361440 NOS | $100.0K | 2 |
| ESOMEPRAZOLE MAGNESIUM DR CAPSULES USP 40MG 30S 63528 X 30S PACKS=1905840 NOS | $100.0K | 2 |
| OMEZ 40 OMEPRAZOLE CAPSULES 40MG 28SPACK 23664 X 28S PACK | $100.0K | 2 |
| OMEPRAZOLE DELAYED-RELEASE CAPSULES USP40MG 30 S 115248 X 30 S PACKS = 3457440NOS | $100.0K | 2 |
| ESOMEPRAZOLE MAGNESIUM DELAYED-RELEASE CAPSULES USP 40 MG 1000 S 1752 X 1000 SPACKS= 1752000 NOS | $88.1K | 2 |
| ESOMEPRAZOLE MAGNESIUM DELAYED-RELEASE CAPSULES USP 20 MG 90 S 16968 X 90 S PACKS = 1527120 NOS | $76.3K | 2 |
DR Reddy S Laboratories Limited exports 320 distinct Omeprazole formulations including tablets, capsules, syrups, and combination drugs. The top formulation is OMEPRAZOLE MAGNESIUM DELAYED RELEASE with 15 shipments worth $748.6K. Notable combination products include fixed-dose combinations with other active ingredients, meeting diverse global regulatory requirements.
Regulatory Requirements: Exporting Omeprazole to Key Markets
What DR Reddy S Laboratories Limited must comply with to export Omeprazole to its top destination countries
United States — FDA
Approval Process
ANDA (Abbreviated New Drug Application) for generics. Indian manufacturing site must pass FDA pre-approval inspection. Drug Master File (DMF) required for APIs.
Timeline: 10–18 months for ANDA approval
GMP & Export Requirements
FDA cGMP compliance (21 CFR 210/211); facility inspection by FDA
Drug Listing with FDA; Export Certificate from CDSCO India; Import Alert screening via FDA PREDICT system
Note: Subject to FDA Import Alerts. Open Form 483 observations can block all exports from a facility.
South Africa — SAHPRA
Approval Process
Registration under SAHPRA guidelines (CTD format). Bioequivalence required for generics.
Timeline: 24–48 months (significant backlog)
GMP & Export Requirements
WHO GMP or PIC/S GMP compliance
Certificate of Pharmaceutical Product from CDSCO; Import permit per Section 22A of Medicines Act
Note: Known registration backlog. WHO Prequalification significantly assists the process.
Regulatory information is provided for general reference based on publicly available guidelines. Requirements vary by formulation, dosage form, and therapeutic classification. Exporters should consult qualified regulatory affairs professionals for case-specific guidance.
How Does DR Reddy S Laboratories Limited Compare to Nearest Omeprazole Exporters?
Exporters ranked immediately above and below #9 by export value
| # | Supplier | Export Value | Shipments | Countries | Avg/Shipment |
|---|---|---|---|---|---|
| 5 | MYLAN LABORATORIES LIMITED | $6.7M | 133 | 5 | $50.0K |
| 12 | HETERO LABS LIMITED | $5.7M | 133 | 13 | $43.0K |
| 9 | DR REDDY S LABORATORIES LIMITED ★ | $5.4M | 108 | 9 | $50.0K |
| 13 | TORRENT PHARMACEUTICALS LTD | $5.2M | 210 | 24 | $24.8K |
| 15 | CAPLIN POINT LABORATORIES LIMITED | $5.1M | 135 | 10 | $37.9K |
DR Reddy S Laboratories Limited ranks #9 among 975 Indian Omeprazole exporters. Average shipment value of $50.0K compared to the market average of $254.4K. The closest competitors by value are MYLAN LABORATORIES LIMITED and HETERO LABS LIMITED.
Which Indian Ports Ship Omeprazole Exports?
| Port | Shipments | % Share |
|---|---|---|
| NHAVA SHEVA SEA (INNSA1) | 1,900 | 12.7% |
| SAHAR AIR CARGO ACC (INBOM4) | 1,316 | 8.8% |
| DELHI AIR CARGO ACC (INDEL4) | 857 | 5.7% |
| SAHAR AIR | 837 | 5.6% |
| JNPT/ NHAVA SHEVA SEA | 784 | 5.2% |
| HYDERABAD ICD (INSNF6) | 480 | 3.2% |
| Bombay Air | 463 | 3.1% |
| DELHI AIR | 456 | 3.0% |
What Other Gastrointestinal Products Does DR Reddy S Laboratories Limited Export?
DR Reddy S Laboratories Limited also exports these gastrointestinal products. Each links to the detailed product page.
Geopolitical & Trade Policy Impact on DR Reddy S Laboratories Limited's Omeprazole Exports
The current geopolitical landscape presents both challenges and opportunities for Indian pharmaceutical exporters like Dr. Reddy's. The Israel-Iran tensions have led to disruptions in Red Sea shipping routes, increasing shipping costs and transit times. This situation necessitates strategic logistics planning to mitigate potential delays and cost escalations.
Conversely, the ongoing US-China trade tensions have prompted the United States to diversify its pharmaceutical supply chain, creating opportunities for Indian exporters. Dr. Reddy's, with its established presence and compliance with stringent regulatory standards, is well-positioned to capitalize on this shift.
In the European Union, compliance with the Falsified Medicines Directive (FMD) remains a critical requirement. Dr. Reddy's commitment to quality and regulatory adherence ensures its continued access to the EU market, despite the evolving regulatory landscape.
DR Reddy S Laboratories Limited — Regulatory Compliance & Quality Standards
Maintaining compliance with international regulatory standards is paramount for Dr. Reddy's. The company has consistently adhered to FDA, WHO, and EU Good Manufacturing Practices (GMP), ensuring the quality and safety of its products. This commitment is crucial in sustaining trust and credibility in global markets.
However, regulatory challenges persist. In April 2025, Dr. Reddy's received a show cause notice from the Indian Income Tax Department concerning a proposed demand of over ₹2,395 crore related to the merger of Dr. Reddy's Holding Ltd with itself. The company has stated its belief that there is no tax liability arising from the merger and is addressing the matter through appropriate channels. (business-standard.com)
About DR Reddy S Laboratories Limited
DR Reddy S Laboratories Limited exports 50 products worth $310.6M. Beyond Omeprazole, top products include Metoprolol, Fexofenadine, Clopidogrel, Esomeprazole, Magnesium. View the complete DR Reddy S Laboratories Limited profile for full portfolio analysis.
Market Intelligence
Latest developments and market context
Detailed market intelligence for Omeprazole — including regulatory updates, trade policy changes, and competitive landscape analysis — will be available in an upcoming update. This section will feature AI-researched insights from verified industry sources, government notifications, and market reports.
Official References & Regulatory Resources
- CDSCO India
- Pharmexcil
- IBEF — India Pharma Industry
- Ministry of Commerce — Pharma Exports
- India Trade Statistics (DGFT)
Verify manufacturer licensing and export certifications with the official agencies above.
Research Methodology & Data Transparency
Suresh Sormare
Verified AuthorPharmaceutical Export-Import Analyst & Trade Intelligence Expert
Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.
linkedin.com/in/sureshsormarePrimary Data Source
All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.
Analysis Methodology
- 1.Product Matching: Omeprazole shipments identified using fuzzy matching on DGFT product description fields, validated against Indian Pharmacopoeia nomenclature.
- 2.Supplier Identification: DR Reddy S Laboratories Limited matched across shipments using name normalization, accounting for company name formatting variations.
- 3.Statistical Normalization: Shipment values are statistically normalized to ensure accurate market share representation. This removes the impact of unusually large one-off transactions that could distort company rankings.
- 4.Verified Records: This page is backed by 377 individual customs records matching DR Reddy S Laboratories Limited exporting Omeprazole, covering 320 formulations to 14 countries via 59 buyers.
Government-Sourced Data
Official DGFT customs records
Transparent Methodology
Calculations fully disclosed above
Global Coverage
Exports to 179+ countries, 2,858+ buyers
Expert-Reviewed
Analyzed by pharmaceutical trade specialists
Get Omeprazole Export Data from DR Reddy S Laboratories Limited
Access shipment-level details, pricing data, buyer connections, and competitive analysis for DR Reddy S Laboratories Limited's Omeprazole exports. TransData Nexus provides verified Indian Customs (DGFT) data trusted by pharmaceutical trade professionals worldwide.
DR Reddy S Laboratories Limited
Full Company Profile →
50 products · $310.6M total trade · 19 categories
Omeprazole Stats
Company Overview
Top Products by DR Reddy S Laboratories Limited
Related Analysis
Need Detailed Export Data?
Access shipment-level records, pricing trends, and buyer contacts for DR Reddy S Laboratories Limited.
Request DemoView Pricing →Data Source
Trade data sourced from Indian Customs (DGFT) export shipment records. Values represent FOB export value in USD. Market share calculated relative to total Indian pharmaceutical exports for Omeprazole. For current shipment-level data, contact TransData Nexus.